International Journal of Tuberculosis and Lung Disease

Papers
(The TQCC of International Journal of Tuberculosis and Lung Disease is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The impact of COVID-19 on TB: a review of the data178
Clinical standards for the assessment, management and rehabilitation of post-TB lung disease78
The Global Asthma Report 202278
Impact of COVID-19 on TB diagnosis in Northeastern Brazil44
Post-TB health and wellbeing36
Clinical standards for the diagnosis, treatment and prevention of TB infection35
The COVID-19 and TB syndemic: the way forward34
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB30
Clinical standards for the dosing and management of TB drugs28
The burden and determinants of post-TB lung disease25
Persistent chronic respiratory symptoms despite TB cure is poorly correlated with lung function23
Diagnosing pulmonary aspergillosis is much easier than it used to be: a new diagnostic landscape23
Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities22
Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?22
The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination20
Comparative analysis of Truenat™ MTB Plus and Xpert® Ultra in diagnosing tuberculous meningitis20
Thrombotic events and COVID-19 vaccines20
Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic19
A randomised controlled trial to evaluate a medication monitoring system for TB treatment18
Chronic obstructive pulmonary disease in sub-Saharan Africa18
Real-world implementation of video-observed therapy in an urban TB program in the United States18
WHO drug-resistant TB guidelines 2022: what is new?18
TB and COVID-19 co-infection: rationale and aims of a global study18
Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes17
Resource reprioritisation amid competing health risks for TB and COVID-1917
Person-centred care in TB17
Mortality due to TB-COVID-19 coinfection in India17
TB multimorbidity: a global health challenge demanding urgent attention16
Non-hospitalised COVID-19 patients have more frequent long COVID-19 symptoms16
Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis16
Management of rifampicin‐resistant TB: programme indicators and care cascade analysis in South Africa16
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts15
Bedaquiline for multidrug-resistant TB in paediatric patients15
Determining the value of TB active case-finding: current evidence and methodological considerations15
UNITE4TB: a new consortium for clinical drug and regimen development for TB14
First molecular-based anti-TB drug resistance survey in Eritrea14
Availability of diagnostic services and essential medicines for non‐communicable respiratory diseases in African countries14
New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India13
Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil13
Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis13
Cost of TB services in healthcare facilities in Kenya (No 3)13
Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV13
The war in Ukraine and potential consequences for the TB epidemic in Europe12
Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis12
Impact of mental disorders on active TB treatment outcomes: a systematic review and meta-analysis11
Chronic respiratory disease in adult outpatients in three African countries: a cross-sectional study11
VIDAS® TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB11
Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients11
Clinical utility of target-based next-generation sequencing for drug-resistant TB11
The scientific response to TB – the other deadly global health emergency11
Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries11
Knowledge, attitudes and practices on childhood TB among healthcare workers10
Depression, stigma and quality of life in people with drug-susceptible TB and drug-resistant TB in Vietnam10
National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 202210
The impact of COVID-19 on the diagnosis of TB in Taiwan10
Minimal clinically important difference of the 6-min walking test in patients with asthma10
Number needed to screen for TB in clinical, structural or occupational risk groups10
Risk factors for chronic pulmonary aspergillosis in post-TB patients10
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB10
Global Asthma Report 2022: a wake-up call to enhance care and treatment for asthma globally9
The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing9
Outdoor air pollution and respiratory health9
COPD exacerbation rates are higher in non-smoker patients in India9
A systematic review of the number needed to screen for active TB among people living with HIV9
The diagnosis of lung cancer in the era of interventional pulmonology9
Two parallel pandemics: the challenges faced by countries with COVID-19 and TB9
QT prolongation in the STREAM Stage 1 Trial9
Air conditioners, airborne infection prevention and air pollution in buildings in New Delhi9
Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men9
Diurnal variability of fine-particulate pollution concentrations: data from 14 low- and middle-income countries9
Work-related interstitial lung disease: what is the true burden?8
Impact of COVID-19 on patients with asthma8
Health-related quality of life associates with clinical parameters in patients with NTM pulmonary disease8
Implementing 3HP vs. IPT as TB preventive treatment in Pakistan8
Country differences and determinants of yield in programmatic migrant TB screening in four European countries8
TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up8
Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring8
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications8
The Asthma Drug Facility and the future management of asthma8
Treatment outcomes and safety in children with rifampicin-resistant TB7
Decreased notification of TB cases during the COVID-19 pandemic7
Clinical standards for drug-susceptible pulmonary TB7
Complications of tuberculous meningitis and their effect on outcome in a tertiary care cohort7
Planning for TB elimination in Lebanon7
Costs of TB services in India (No 1)7
The economic burden of TB-affected households in DR Congo7
Best practices for the care of pregnant people living with TB7
Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults7
Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens7
Opportunities to prevent and manage undernutrition to amplify efforts to end TB7
Cost of TB services in the public and private sectors in Georgia (No 2)7
The 100th anniversary of bacille Calmette-Guérin (BCG) and the latest vaccines against COVID-197
Diagnosis patterns for rifampicin-resistant TB after onset of COVID-197
Increase in disseminated TB during the COVID‐19 pandemic6
Continuity of TB services during the COVID-19 pandemic in China6
Xpert® MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates6
Post-TB bronchiectasis: from pathogenesis to rehabilitation6
Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines6
Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB6
The impact of COVID-19 on the TB response: data from the field6
CAD4TB software updates: different triaging thresholds require caution by users and regulation by authorities6
Active case‐finding in contacts of people with TB6
Effect of 6-month vs. 8-month regimen on retreatment success for pulmonary TB6
The effect of systematic screening of the general population on TB case notification rates6
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB6
Using a mobile application to improve pediatric presumptive TB identification in western Kenya6
An Inca trail to the Holy Grail: digital medication adherence support for TB care6
Towards quality adolescent-friendly services in TB care6
Post-TB disease: a new topic for investigation—and why it matters6
Impact of influenza A co-infection with COVID-196
A comparative analysis of asthma treatment guidelines and Essential Medicine Lists in sub-Saharan Africa6
Screening for active and latent TB among migrants in France6
Whole-genome sequencing differentiates relapse from re-infection in TB5
Guidance is needed to mitigate the consequences of analytic errors during antimicrobial susceptibility testing for TB5
Trends in rifampicin and isoniazid resistance in patients with presumptive TB5
Xpert Ultra in diagnosing extrapulmonary TB: accuracy and trace calls5
Impact of lung function on treatment outcome in patients with TB5
Fluoroquinolone preventive therapy for children exposed to MDR-TB5
Determinants of treatment outcomes in patients with multidrug-resistant TB5
COVID-19 and TB: a progression-regression conundrum5
An approach for improving the quality of country-level TB modelling5
TB in the elderly: clinical features and outcomes5
Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes5
Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan5
Sputum culture conversion definitions and analytic practices for multidrug-resistant TB5
Finding gaps in routine TB surveillance activities in Bangladesh5
Cost of TB services: approach and summary findings of a multi-country study (Value TB)5
Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children5
Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB5
Childhood TB in China: notification, characteristics and risk factors for outcomes, 2010–20175
TB in older people in Asia: why it is important5
Incremental yield of Xpert® MTB/RIF Ultra over Xpert® MTB/RIF in the diagnosis of extrapulmonary TB5
Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial5
Gender differences in health-seeking behaviour, diagnosis and treatment for TB5
How mechanistic in silico modelling can improve our understanding of TB disease and treatment5
Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study5
Sustained effect of isoniazid preventive therapy among household contacts in Brazil5
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus5
Undernutrition can no longer be an afterthought for global efforts to eliminate TB5
Time for a change: considering regimen changes in analyses of observational drug-resistant TB treatment cohort data5
Preventive treatment of drug-resistant TB in a rural setting4
Digital adherence technology for TB: focus on livelihoods as well as lives4
Impact of COVID-19 on TB epidemiology in South Korea4
Prevention care cascade in people exposed to drug-resistant TB4
eHealth in TB clinical management4
Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline4
Smoked drug use in patients with TB is associated with higher bacterial burden4
Psychological distress among TB patients in sub-Saharan Africa4
TB screening, prevention and treatment cascade in a Malawi prison4
Reducing the burden of TB among migrants to low TB incidence countries4
Clinical standards for drug-susceptible TB in children and adolescents4
The effect of incarceration on TB treatment outcomes4
Adipokines and the risk of active TB: a nested case-control study4
High‐resolution CT in smoking‐related interstitial lung diseases4
Impact of COVID-19 on TB services in Korea4
How much does TB screening cost? A systematic review of economic evaluations4
Systematic rifampicin resistance errors with Xpert® MTB/RIF Ultra: implications for regulation of genotypic assays4
Ratios from full blood count as markers for TB diagnosis, treatment, prognosis: a systematic review4
GPT-4, artificial intelligence and implications for publishing4
Prevalence, knowledge and factors associated with shisha smoking among university students in Cameroon4
Prevalence of and risk factors for depressive symptoms in non-tuberculous mycobacterial pulmonary disease4
Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert® MTB/RIF4
Clinical standards for the management of adverse effects during treatment for TB4
Impact of the COVID-19 pandemic on TB infection testing4
Tobacco use and quitting behaviour during COVID-19 lockdown4
The impact of smoking on TB treatment outcomes includes recurrent TB4
Lung function decline in non-tuberculous mycobacterial pulmonary disease according to disease severity4
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries4
Diabetes mellitus is not a predictor of poor TB treatment outcomes4
TB testing in HIV-positive patients prior to antiretroviral treatment4
Case-control study of vitamin D status and adult multidrug-resistant pulmonary TB4
Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting4
Completion of treatment for latent TB infection in a low prevalence setting4
Feasibility and acceptability of asynchronous VOT among patients with MDR-TB4
Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era4
In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes4
Early mortality during rifampicin-resistant TB treatment4
Isoniazid preventive therapy among child contacts of TB patients, India4
Extemporaneously compounded liquid formulations of clofazimine4
The effect of medication event reminder monitoring on treatment adherence of TB patients4
A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients4
Adverse effects and duration of treatment of TB in Canterbury, New Zealand4
Decline in TB incidence during the COVID-19 pandemic3
A self-rated health score predicts severe disease and high mortality in patients with pulmonary TB3
Cost of TB prevention and treatment in the Philippines in 20173
Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services3
Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia3
Epidemiology and clinical characteristics of childhood TB identified using active and passive case finding3
Engaging private pharmacies to help end TB in India3
Recent epidemiological trends in extrapulmonary TB in Galicia, Spain3
Post-COVID-19 tomographic abnormalities3
Avoiding pitfalls in calculating the population attributable fraction of undernutrition for TB3
Parental TB associated with offspring asthma and rhinitis3
The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London3
Concomitant pulmonary disease is common among patients with extrapulmonary TB3
Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen3
Use of chest radiography screening for TB: a re-evaluation of the Kolín study3
TB and chronic pulmonary aspergillosis: a few relevant points3
TB in ageing populations: lessons from Japan and Korea3
Prevalence of TB and health-seeking behaviour3
Diagnosis of paediatric TB using Xpert® MTB/RIF Ultra on fresh respiratory samples3
Demographic and socio-economic risk factors associated with self-reported TB3
Risk factors for the delayed diagnosis of extrapulmonary TB3
Clinical effects of TB sequelae in patients with COPD3
Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children3
Cost to perform door-to-door universal sputum screening for TB in a high-burden community3
TB screening of Ukrainian refugees in Germany3
Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field3
Ethambutol-induced optic neuropathy in nontuberculous mycobacterial disease3
TB in children and adolescents3
TB research amidst the COVID-19 pandemic3
Determinants of non-adherence to anti-TB treatment in high income, low TB incidence settings: a scoping review3
Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes3
Perceived stigma among people with TB and household contacts3
User perspectives on the use of X-rays and computer-aided detection for TB3
‘One Health´ approach to end zoonotic TB3
Infection status of contacts is not associated with severity of TB in the index case3
TB preventive therapy preferences among children and adolescents3
WHO target product profiles for TB preventive treatment3
Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand3
A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings3
Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries3
Changes to TB care in an outpatient centre during the COVID‐19 pandemic3
Initial experience with BPaL-based regimens to treat multidrug-resistant TB3
Chronic pulmonary aspergillosis as a sequel to pulmonary TB3
TB case fatality and recurrence in a private sector cohort in Mumbai, India3
Clinical care for patients with post-TB lung disease3
Call to action for an invigorated drive to scale up TB prevention3
TB‐related knowledge and stigma among pregnant women in low‐resource settings3
Updated guidelines for child and adolescent TB3
TB and COVID-19 coinfection3
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova3
Costs along the TB diagnostic pathway in Uganda3
Assessment of asthma control in users of oral anti-asthma medications3
Digital approaches to reducing TB treatment loss to follow-up3
Progress on indoor air quality regulation in India3
Recent developments in the diagnosis and treatment of extrapulmonary non-tuberculous mycobacterial diseases3
IGRA test for TB in COVID-19: role of corticosteroids3
Stool testing for pulmonary TB diagnosis in adults3
Shortening MDR-TB treatment: is treating more patients with fewer drugs better?3
0.098473072052002